AbbVie Inc (ABBV)vsBright Minds Biosciences Inc (DRUG)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
DRUG
Bright Minds Biosciences Inc
$89.11
+0.13%
HEALTHCARE · Cap: $872.62M
Smart Verdict
WallStSmart Research — data-driven comparison
ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
DRUG
Avoid22
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for DRUG.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
No standout strengths identified
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
Trading at 10.6x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : DRUG
DRUG has a balanced fundamental profile.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : DRUG
The primary concerns for DRUG are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ABBV is growing revenue faster at 10.0% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ABBV scores higher overall (63/100 vs 22/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Bright Minds Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Bright Minds Biosciences Inc. (DRUG) is a pioneering clinical-stage biotechnology firm dedicated to developing cutting-edge therapies aimed at addressing central nervous system disorders, particularly in mental health and pain management. Leveraging its proprietary drug development platform, the company is advancing a robust pipeline of candidates that prioritize both efficacy and safety, amidst the increasing acceptance of psychedelic treatments. With a seasoned management team and a strong intellectual property portfolio, Bright Minds is strategically positioned to capture the growing demand for innovative mental health solutions, making it an attractive prospect for institutional investors seeking exposure to the evolving pharmaceutical landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?